SKI-I is primarily used in research settings to study and inhibit the Sphingosine Kinase (SK) enzyme, which plays a critical role in cellular signaling pathways. Its application is significant in understanding the mechanisms of cancer, as SK is often overexpressed in various tumor types. By blocking SK activity, SKI-I helps researchers explore potential therapeutic strategies for cancer treatment. Additionally, it is utilized in studies related to inflammation and immune responses, as SK is involved in the regulation of these processes. SKI-I serves as a valuable tool in preclinical investigations to assess the role of SK in disease progression and to evaluate the efficacy of targeting this enzyme for therapeutic purposes.